

News Release about the acquisition of TCG client, Curasan

DATE: June 16, 2008

CONTACT: Rick Patton, 888-237-2767 or
919-941-9770, rick.patton@curasan.com
Ellen Zimmerman, President, The Zimmerman Group,
540-722-8888, ez@zimm.com

Dental Line of Curasan Inc Acquired by Riemser AG

Research Triangle Park, NC June 16, 2008 —Curasan Inc., based in Research Triangle Park, NC is pleased to announce that Riemser Arzneimittel AG, an established German pharmaceutical company, has purchased the worldwide dental business of curasan AG. The purchase includes our flagship Cerasorb® and REVOIS® products along with several membranes from partner organizations.

With annual revenues of some \$100 million (60 MM Euro in 2006) and 500 employees at four manufacturing and research sites in Europe, Riemser develops and markets a line of successful dental, dermatology, cardiovascular, anti-inflammatory and oncology products.

By purchasing Curasan's dental business, Riemser has expressed a commitment to grow their position in the dental market and to expand the successful US business – a commitment backed by strong financial resources. Cerasorb® DENTAL bone regeneration material and EpiGuide® membrane have doubled in users and sales in each of the past two years, demonstrating their strong impact on the US market.

“We are looking forward to expanding our excellent infrastructure in the United States, and our strong product line. The additional Riemser resources will also support the US launch of REVOIS®, the all-in-one implant system, and other new dental offerings in the future” said Rick Patton, VP Sales of Curasan, Inc.

All Cerasorb® and EpiGuide® programs for dentist and oral surgeons will continue in the US this year, including more than 60 workshops throughout the country and participation in major meetings for oral surgeons, periodontists and implantology specialists.

###